trial

Exploratory Study of a Digital Therapeutics in People With Schizophrenia

NCTId NCT05438160
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 48 (actual)
Sponsored by Click Therapeutics, Inc.
Primary completion 2022-07-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-03-31
Primary completion
2022-07-31
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Clinical Learning Study smartphone app (i.e., the study app)

Sponsors

Click Therapeutics, Inc.Lead Sponsor
Boehringer IngelheimCollaborator

Investigators

1
Shaheen Lakhan, MDPhD, FAANStudy Chair

Sites

7 total
Anaheim, United StatesTorrance, United StatesHialeah, United StatesLake Mary, United StatesMiami, United StatesIrving, United StatesRichmond, United States

Facts & assertions

4 sourced
Enrollment
48
Phase
NA
Primary Completion Date
2022-07-31
Status
COMPLETED
relationships
The graph out of here
drug
Clinical Learning Study smartphone app (i.e., the study app)
drug
lead_sponsor
Click Therapeutics, Inc.
company
collaborator
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Shaheen Lakhan, MDPhD, FAAN
person